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Abstract
Multiple system atrophy (MSA) is a fatal oligodendrogliopathy characterized by prominent -synuclein inclusions resulting in a neuronal
ultisystem degeneration. Until recently MSA was widely conceived as a nongenetic disorder. However, during the last years a few
ostmortem verified Mendelian pedigrees have been reported consistent with monogenic disease in rare cases of MSA. Further, within the
ast 2 decades several genes have been associated with an increased risk of MSA, first and foremost the SNCA gene coding for -synuclein.
oreover, genes involved in oxidative stress, mitochondrial dysfunction, inflammatory processes, as well as parkinsonism- and ataxia-
elated genes have been implicated as susceptibility factors. In this review, we discuss the emerging evidence in favor of genetic players
n MSA.
 2011 Elsevier Inc. Open access under CC BY-NC-ND license.
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S1. Introduction
Multiple system atrophy (MSA) is a progressive neuro-
degenerative movement disorder characterized by auto-
nomic failure, poorly levodopa-responsive parkinsonism,
cerebellar ataxia, and pyramidal symptoms in variable com-
binations. Neuronal cell loss in the basal ganglia, cerebel-
lum, pontine and inferior olivary nuclei, pyramidal tract,
intermediolateral cell column, and Onuf’s nucleus as well as
gliosis are typically observed (Wenning et al., 2004). MSA
is commonly regarded as a primary oligodendrogliopathy
(Wenning et al., 2008) because of widespread glial cyto-
plasmic inclusions (GCIs; Papp-Lantos bodies) that are seen
even in brain areas without evident neuronal loss. GCIs
were first identified in 1989 using Gallyas silver impregna-
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doi:10.1016/j.neurobiolaging.2011.04.001tion (Gallyas and Wolff, 1986; Papp et al., 1989) and were
later shown to be immunoreactive for -synuclein (Lantos,
998; Wakabayashi et al., 1998), thereby linking MSA with
ther synucleinopathies, such as Parkinson’s disease (PD)
nd dementia with Lewy bodies (DLB) (Spillantini et al.,
998). Genetic studies have shown that variants in the
NCA gene, coding for -synuclein, are major risk factors
for MSA (see section 4.1). This recent finding represents a
major breakthrough in our understanding of MSA.
Apart from the role of the SNCA gene, the etiopathogen-
esis of MSA is still enigmatic. Interactions of genetic and
environmental factors, similar to other complex, sporadic
neurodegenerative diseases, are likely (Brown et al., 2005).
In a few controlled studies, an increased risk of developing
MSA conferred by occupational and daily habits, such as
exposure to solvents, additives, plastic monomers, metals,
and various other toxins (Gilman et al., 1998; Nee et al.,
1991; Vanacore, 2005), as well as a history of farming
(Brown et al., 2005; Vidal et al., 2008) has been observed.
A recent study, however, questioned some of these associ-
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from environmental studies are hard to obtain due to limit-
ing factors such as recall (overreporting of exposure) and
selection bias (patients with severe diseases are less able to
participate) (Stefanova et al., 2009). Thus the role of envi-
ronmental factors is far from clear.
A disease-causing gene has not been identified in the few
postmortem proven MSA pedigrees that will be reviewed
here; however, these families indicate that monogenic MSA
may occur (Hara et al., 2007; Wullner et al., 2004). In this
article, we provide an update on genetic studies in MSA and
discuss how they may increase our understanding of the
pathogenesis of this devastating disorder.
2. Familial and monogenic MSA
Familial aggregation has been consistently documented
for PD (Thacker and Ascherio, 2008) but only rare reports
of familial MSA exist (Hara et al., 2007; Soma et al., 2006;
Wullner et al., 2004). A recent study found a higher fre-
quency of parkinsonism among first-degree relatives of
MSA patients (Vidal et al., 2010). This is consistent with
earlier findings reporting that 13% of MSA patients had at
least 1 first-degree or second-degree relative with parkin-
sonism (Wenning et al., 1993) and that higher frequencies
of neurological disease occur among first-degree relatives of
MSA patients (Nee et al., 1991). In contrast, a positive
family history for PD has not been shown to be a risk factor
for MSA (Vanacore et al., 2005).
Only a few familial cases with MSA have been reported.
One German family with probable MSA affecting 2 mem-
bers in 2 successive generations was described (Wullner et
al., 2004). Genetic testing excluded spinocerebellar ataxia
(SCA) types 1–3, 6, 7, and 17 as well as mutations in the
-synuclein gene (Ozawa et al., 1999; Wullner et al., 2004).
One affected patient died subsequently and the diagnosis
was confirmed according to standard neuropathological cri-
teria (Trojanowski and Revesz, 2007; Wullner et al., 2009).
A second family was reported in which a female patient
with probable MSA had a father who was diagnosed at first
with cortical cerebellar atrophy (CCA) and after developing
orthostatic hypotension a few months later with probable
MSA (Soma et al., 2006). Pedigree structure in both of these
families was consistent with autosomal dominant inheri-
tance.
In 2007, 4 Japanese MSA families with multiple affected
siblings were reported (Hara et al., 2007). One patient had
definite MSA, 5 patients were diagnosed with probable
MSA, and the remaining 2 patients had possible MSA.
Because a consanguineous marriage was noted for 1 family,
both men and women were affected and because none of the
affected individuals were ascertained in successive genera-
tions, an autosomal recessive mode of inheritance is likely.
Mutational analysis of the coding regions of SNCA, how-
ever, failed to identify any mutations (Hara et al., 2007).SNCA missense and multiplication mutations are a rare
cause of parkinsonism. To date only a few families have
been described with duplication or triplication mutations
involving this locus (Fuchs et al., 2007; Polymeropoulos et
al., 1997; Singleton et al., 2003). Clinical symptoms of
SNCA multiplication patients sometimes resemble symp-
toms usually seen in MSA, suggesting that the clinical
phenotype can be more variable and does not necessarily
resemble that of idiopathic PD (Fuchs et al., 2007). Further-
more, neuropathological studies in SNCA triplication cases
demonstrated GCI-like inclusions in addition to Lewy bod-
ies (Farrer et al., 2004; Gwinn-Hardy et al., 2000; Muenter
et al., 1998; Waters and Miller, 1994).
In order to shed more light on the genetic background
and a possible hereditary component of MSA, it is therefore
crucial to ascertain informative families for systematic ge-
netic screening. Efforts are underway to sequence the ex-
ome, which is the entire coding sequence of the genome, in
familial MSA cases in an attempt to identify disease-caus-
ing mutations.
3. Genocopies of familial MSA
MSA patients share some clinical features, such as prom-
inent ataxia, dysmetria, and eye movement abnormalities,
with autosomal dominant spinocerebellar ataxias (SCAs)
(Schols et al., 2004). For instance, an MSA-C-like presen-
tation has been reported for a family with SCA1 triplet
repeat expansion (Gilman et al., 1996). Neuropathological
changes involved not only cerebellum and brainstem, but
also basal ganglia, thalamus, and intermediolateral columns
of the spinal cord; furthermore tau- and ubiquitin-positive
GCIs were reported. Several features of the index patient,
however, were found to be unusual for MSA including early
disease onset, cerebellar and autonomic features in the ab-
sence of any pyramidal or extrapyramidal signs, as well as
sparse argyrophillic inclusions positive for tau and ubiqui-
tin. Unfortunately, -synuclein immunostaining was un-
available at the time of the study and therefore a definitive
diagnosis of MSA could not be made (Lantos, 1998; Tro-
janowski and Revesz, 2007).
Berciano and Ferrer (1996) reported ubiquitin-positive
GCIs in a patient with familial olivoponto-cerebellar atro-
phy (OPCA). A molecular genetic analysis in the patient’s
son showed CAG repeat expansion in the SCA2 gene. The
proband’s material was re-examined and immunohisto-
chemistry showed ubiquitin-positive, -synuclein-negative
GCI-like inclusions (Berciano and Ferrer, 2005). Hence, in
the absence of -synuclein-positive GCIs, it is recom-
mended to avoid the use of the term MSA to designate any
familial ataxia (Gilman et al., 1996).
An intriguing case of SCA3 resembling MSA-C was
reported recently (Nirenberg et al., 2007). Pathological
changes met the consensus criteria for definite MSA (Gil-
man et al., 1999), including the presence of typical, -sy-
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changes in the olivopontocerebellar, striatal, and pyramidal
motor system. However, SCA3 expansions were not de-
tected in a study of 80 Caucasian subjects with the clinical
diagnosis of MSA indicating that SCA3 expansions are not
a common cause of MSA (Bandmann et al., 1997). Despite
this observation, SCA3 gene variants might act as suscep-
tibility factors for the development of MSA-C (Nirenberg et
al., 2007).
SCA6 accounts for less than 10% of patients with spo-
radic adult-onset ataxia (Abele et al., 2002), and it may
rarely be confused with MSA because of associated
levodopa-refractory parkinsonism (Khan et al., 2005). A
screening study in Japanese patients, however, did not re-
veal any individuals with trinucleotide repeat expansions in
the SCA6 gene, indicating that SCA6 is not commonly
associated with MSA (Furiya et al., 2005).
Factor and colleagues reported an ataxia patient with
unstable CTA/CTG repeats in the SCA8 allele and a brain
pathology consistent with MSA (Lantos and Papp, 1994)
including ubiquitin- and -synuclein-positive GCIs (Factor
et al., 2005). Repeat expansions in this gene were not
observed in a Japanese study, suggesting that SCA8-related
neurodegeneration is a rare genocopy of MSA (Furiya et al.,
2005).
SCA17 is rare among the dominant ataxias (Schols et al.,
2004). Interestingly, pathogenic trinucleotide repeat expan-
sions have been reported in several patients with SCA17-
related neurodegeneration, presenting with MSA-like
features such as ataxia, cerebellar atrophy, urinary inconti-
nence, postural instability, and bradykinesia (Kim et al.,
2009; Lin et al., 2007). However, a subsequent candidate
gene screening study in Japanese MSA patients did not
reveal pathogenic repeat expansions (Furiya et al., 2005).
The SCAs and other hereditary ataxias such as Fried-
reich’s ataxia (FA) and fragile X-associated ataxia syn-
drome (FXTAS) can present as an apparently sporadic dis-
order. It has been shown that even in ataxia patients with a
negative family history there is a 15%–20% chance of a
mutation (Abele et al., 2002). For instance, a study of 112
sporadic, late-onset ataxia patients found that 32 patients
(29%) met the clinical criteria of possible (7%) or probable
(22%) MSA. The Friedreich’s ataxia mutation was found in
5 patients (4%), the SCA2 mutation in 1 (1%), the SCA3
mutation in 2 (2%), and the SCA6 mutation in 7 patients
(6%) (Abele et al., 2002).
Clinical overlap with MSA has also been reported for
FXTAS because both disorders are characterized by mid-to
late-onset cerebellar ataxia, levodopa-unresponsive parkin-
sonism, and autonomic features (Kamm et al., 2005). This
similarity led to the assumption that a premutation in the
fragile X mental retardation gene 1 (FMR1) could be a
susceptibility gene mutation of MSA (Yabe et al., 2004). A
study performed in Japanese MSA patients failed to support
an association of FMR1 premutations and MSA (Yabe et ial., 2004). Data from the European MSA study group also
suggest that probable MSA is only rarely associated with
FMR1 premutations and confusing FXTAS with MSA is
very unlikely (Kamm et al., 2005).
In summary, genetic testing for SCA genes in MSA
patients should not be considered as a routine clinical pro-
cedure, particularly because SCAs are generally of early-
onset, slow in progression, and mainly present in patients
with a positive family history. Nevertheless, presence of
“red flags” raising doubts about a diagnosis of MSA should
alert to the possibility of an inherited ataxia, in which case
genetic testing for the above discussed genes can be initi-
ated.
4. Risk loci in MSA
4.1. SNCA
The presence of -synuclein immunoreactive GCIs in
SA places the disease amongst the broad category of
ynucleinopathies including PD as well as DLB (Spillantini
t al., 1998), and because of its fundamental role in MSA
athology, subsequent genetic approaches focused on the
orresponding SNCA gene. Sequencing studies, gene dosage
easurements, microsatellite testing, as well as a haplotype
agging approach failed to demonstrate a significant associ-
tion of SNCA variants with MSA (Lincoln et al., 2007;
orris et al., 2000; Ozawa et al., 1999, 2006). This might
ave been because of the small sample size involved in
hese studies or because of common misdiagnosis in clini-
ally ascertained cases.
In 2009, Scholz and colleagues demonstrated by a candi-
ate single nucleotide polymorphism (SNP) association study
hat genetic variants within the SNCA locus are associated with
n increased risk for developing MSA in Caucasian individuals
most significant single nucleotide polymorphism rs11931074:
-value under recessive model  5.5  1012, odds ratio for
omozygous risk allele carriers  6.2 [95% confidence inter-
al, 3.4–11.2]) (Scholz et al., 2009). This result has been
ubsequently replicated in an independent set of autopsy-
roven MSA cases (Ross et al., 2010). Furthermore, genetic
isk variants in SNCA have also been replicated by Al-Chalabi
and colleagues (Al-Chalabi et al., 2009), although this study
was not independent, as a large proportion of the investigated
samples have been previously tested in the original study by
Scholz and colleagues.
The identified risk variants are located in a haplotype
block that extends from intron 4 to the 3= untranslated
region of the SNCA gene (Fig. 1) and are in strong linkage
isequilibrium. It is of note, that the very same risk variants
re also significantly associated with risk for PD (Satake et
l., 2009; Simón-Sánchez et al., 2009), indicating shared
athogenic mechanisms between these 2 synucleinopathies.
In contrast, a more recent South Korean study reported
igher frequencies of the previously identified risk variants
n their control cohort and failed to identify an association
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(Yun et al., 2010). This observation suggests population
heterogeneity at the SNCA locus similar to the heterogeneity
escribed for the MAPT, LRRK2 or GBA loci in PD.
It is unclear how the identified SNCA risk haplotype
onfers risk to developing MSA, in particular because
athogenic mutations in the SNCA coding sequence could
not be identified (Ozawa et al., 1999, 2006; Scholz et al.,
2009). Although gene dosage measurements in MSA pa-
tients did not reveal SNCA duplications or triplications (Lin-
coln et al., 2007), modest changes in gene expression could
still be possible. This notion is supported by the observation
that duplication and triplication of SNCA in autosomal dom-
nant PD families can lead to GCI-like inclusions and clin-
cal features of MSA (Fuchs et al., 2007; Gwinn-Hardy et
l., 2000; Singleton et al., 2003). Furthermore, transgenic
nimals overexpressing -synuclein under oligodendroglial
romoters have demonstrated neuropathological findings re-
embling MSA (Kahle et al., 2002; Shults et al., 2005;
azawa et al., 2005).
.2. Candidate gene studies
Until recently, the study of molecular genetic mecha-
Fig. 1. Identified risk variants in a haplotype block extendiisms involved in sporadic diseases was limited to candi-ate gene approaches. While many candidate gene studies
ave provided crucial insights into the pathogenesis of hu-
an disease, it is critical that the interpretation of results
rom candidate gene studies is handled with caution. This is
articularly true for much of the past candidate gene re-
earch in MSA where most studies have a low power due to
mall sample sizes or lack replication stages. Table 1 pro-
ides a brief overview of candidate genes that have been
ested to date. For the purpose of this review article, we will
imit our discussion here to some of the major candidate
enes.
Parkin and PTEN-induced putative kinase 1 (PINK1)
utations are the most common causes of autosomal reces-
ive early-onset PD (Hatano et al., 2009; Nuytemans et al.,
010). A comprehensive mutation screening study investi-
ating the role of genetic variants in parkin and PINK1 in
pathology-proven MSA cases has been recently performed
(Brooks et al., 2011). No clear pathogenic, homozygous
mutations were identified, suggesting that genetic variants
at these loci are not commonly associated with MSA
(Brooks et al., 2011).
Genetic variability at the MAPT locus, coding for micro-
tubule-associated protein tau, has been associated with a
intron 4 to the 3= untranslated region of the SNCA gene.number of neurodegenerative diseases (Abraham et al.,
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testing for a potential effect of MAPT variants on MSA
Table 1
Candidate gene studies in MSA
Positive findings
Familial aggregation
(Hara et al., 2007; Nee et al., 1991; Soma et al., 2006; Vidal et al.,
2010; Wenning et al., 1993; Wullner et al., 2004, 2009)
taxia genes
SCA3 (Nirenberg et al., 2007)
SCA6 (Khan et al., 2005)
SCA8 (Factor et al., 2005)
SCA17 (Kim et al., 2009; Lin et al., 2007)
FA (Abele et al., 2002)
D genes
SNCA (Al-Chalabi et al., 2009; Ross et al., 2010; Scholz et al., 2009)
enes associated with oxidative stress
SLC1A4, SQSTM1, EIF4EBPI (Soma et al., 2008)
enes associated with neuroinflammation
IL-1 (Combarros et al., 2003)
IL-1 (Nishimura et al., 2002)
TNF (Nishimura et al., 2005b)
IL-8/ICAM-1 (Infante et al., 2005)
ACT-A/A (Furiya et al., 2005)
ther genetic risk factors
ADH1C (Schmitt et al., 2006)
ey: ACT-A/A, -1-antichymotrypsin; ADH, alcohol dehydrogenase; AP
ranscription factor 4; BDNF, brain-derived neurotrophic factor; CARS, c
CCAAT/enhancer-binding protein homologous protein; CNTF, ciliary neuro
DAT1, dopamine transporter 1; DBH, dopamine--hydroxylase; DM2, myoto
MR1, fragile X mental retardation 1; GSTM1, glutathione S-transferase M1;
nsulin-like growth factor 1; IL, interleukin; LRRK2, leucine-rich repeat kinase
-acetyltransferase 2; PRGN, progranulin; SCA, spinocerebellar ataxia; SL
GF-1, transforming growth factor-1; TNF-, tumor necrosis factor-; UCfailed to identify significant associations (Morris et al.,2000; Scholz et al., 2009). Along the same lines, mutations
in the LRRK2 and GBA genes, known to be risk factors for
egative findings
anacore et al., 2005)
CA1–3, 6–8, 12,17 (Bandmann et al., 1997; Berciano and Ferrer, 1996,
2005; Berciano et al., 2005; Cho et al., 2008; Gilman et al., 1996)
FMR1 (Kamm et al., 2005; Yabe et al., 2004)
NCA (Lincoln et al., 2007; Morris et al., 2000; Ozawa et al., 1999,
2006)
ynphilin (Brooks et al., 2009; Morris et al., 2000)
INK1 (Brooks et al., 2009)
arkin (Brooks et al., 2009)
RRK2 (Cho et al., 2009; Ozelius et al., 2007; Ross et al., 2006; Tan et
al., 2006)
BA (Goker-Alpan et al., 2006; Segarane et al., 2009)
APT (Morris et al., 2000; Scholz et al., 2009)
YP2D6 (Bandmann et al., 1995; Iwahashi et al., 1995;
lanté-Bordeneuve et al., 1995)
YP1A (Nicholl et al., 1999)
MST1 (Nicholl et al., 1999)
AT2 (Nicholl et al., 1999)
AT1 (Nicholl et al., 1999)
HOP, ATF3, ATF4, CEBPB, CARS (Soma et al., 2008)
-1RA (Nishimura et al., 2002)
-6 (Nishimura et al., 2005b)
-10 (Nishimura et al., 2005b)
GF-1 (Nishimura et al., 2005b)
NF (Infante et al., 2005)
F1 (Bandmann et al., 1997)
DH7 (Buervenich et al., 2000)
RNP (Shibao et al., 2008)
CHL-1 (Healy et al., 2005)
DNF (Nishimura et al., 2005a)
NTF (Bandmann et al., 1997)
F1 (Bandmann et al., 1997)
LA (Bandmann et al., 1997)
GIRK (Bandmann et al., 1997)
BH (Cho et al., 2003)
M2 (Lim et al., 2009)
tDNA (Zhang et al., 2002)
POE (Morris et al., 2000)
GRN (Yu et al., 2010)
olipoprotein E; ATF3, activating transcription factor 3; ATF4, activating
t-RNA synthetase; CEBPB, CCAAT/enhancer-binding protein-; CHOP,
factor; CYP1A1, cytochrome P450 1A1; CYP2D6, cytochrome P450 2D6;
rophy 2; EIF4EBP, eukaryotic translation initiation factor 4E-binding protein;
uman leukocyte antigen; ICAM-1, intercellular adhesion molecule 1; IGF-1,
T, microtubule-associated protein tau; MSA, multiple system atrophy; NAT2,
olute carrier family 1A4; SNCA, -synuclein; SQSTM1, sequestosome 1;
ubiquitin carboxyl-terminal esterase L1.N
(V
S
S
S
P
P
L
G
M
C
P
C
G
N
D
C
IL
IL
IL
T
T
IG
A
P
U
B
C
IG
H
hi
D
D
m
A
P
OE, ap
ysteinyl
trophic
nic dyst
HLA, h
2; MAPPD (Lwin et al., 2004; Segarane et al., 2009; Sidransky,
mb
a
o
(
v
M
i
d
(
t
c
n
2
m
s
i
c
t
k
s
m
b
a
i
w
1924.e10 S. Stemberger et al. / Neurobiology of Aging 32 (2011) 1924.e5–1924.e142006), are not associated with MSA (Ozelius et al., 2007;
Ross et al., 2006; Segarane et al., 2009; Tan et al., 2006).
Recently it has been suggested that oxidative and nitra-
tive stress are associated with the onset and progression of
-synucleinopathies. This theory is based on the observa-
tion of nitrated -synuclein in GCIs and neuronal cytoplas-
ic inclusions in MSA brain samples as well as in Lewy
odies and Lewy neurites of PD and DLB brains (Soma et
l., 2008). Further, in vitro studies have revealed that nitric
xide and superoxide induce -synuclein aggregation
Duda et al., 2000; Soma et al., 2008). Hence, genes in-
olved in oxidative stress are interesting candidate genes for
SA. In a case-control study testing 8 candidate genes
nvolved in oxidative stress significant associations were
emonstrated for SLC1A4, SQSTM1, and finally EIF4EBPI
Soma et al., 2008). Replication studies testing these puta-
ive risk variants still need to be performed to draw final
onclusions on the relevance of these findings.
Microglial activation has been reported to parallel the
euronal multisystem degeneration in MSA (Ishizawa et al.,
004), suggesting neuroinflammation as a key pathogenic
echanism. Activation of microglia produces cytokines,
uch as interleukin-1 (IL-1), IL-1, IL-6, tumor necrosis
factor- (TNF-), chemokines such as IL-8, as well as
nflammatory markers such as intercellular-adhesion mole-
ule-1 (ICAM-1), all of which are known to contribute to
issue injuries (Wyss-Coray and Mucke, 2002). Thus, cyto-
ine gene polymorphisms have been analyzed in several
tudies searching for genetic susceptibilities in MSA. Poly-
orphisms in IL-1 (Combarros et al., 2003), IL-1
(Nishimura et al., 2002), IL-8 (Infante et al., 2005), and
ICAM-1 (Infante et al., 2005) were reported to be associated
with an increased risk of MSA. A similar finding was also
demonstrated for a polymorphism of the -1-antichymot-
rypsin gene (Furiya et al., 2005), as well as for a promoter
region polymorphism in the tumor necrosis factor gene
(Nishimura et al., 2005b). These studies are important, be-
cause they point toward a possible role of neuroinflamma-
tion in disease pathogenesis. Nevertheless, they were per-
formed with a small number of patients and should be
repeated in larger, independent cohorts.
Other risk factors such as mutations in the alcohol de-
hydrogenase genes ADH1C and ADH7 have been analyzed
in MSA patients. The ADHC1 G78X mutation was shown to
be associated with MSA in the British, but not in the
German population (Schmitt et al., 2006), whereas no sig-
nificant associations were detected in ADH7 (Kim and Lee,
2003).
One of the latest discussions in neurological diseases
center on the question of whether neurodegeneration can be
caused in a cell-autonomous manner via independent for-
mation of abnormal protein aggregates in affected brain
cells, or whether propagation of protein misfolding occurs
through mechanisms similar to those underlying prion dis-
eases (Goedert et al., 2010). An intriguing case of MSAfollowed by sporadic prion disease has been published (Shi-
bao et al., 2008). Genetic analysis of this patient did not
reveal any mutations in the prion protein gene (PRNP), but
it was noted that the proband was MM homozygous for the
common M129V polymorphism (Shibao et al., 2008). A
case-control study was initiated to investigate a possible
connection between the M129V polymorphism and MSA
(Shibao et al., 2008). The study revealed that the homozy-
gotes are associated with an increased risk of MSA and
earlier disease onset compared with PD subjects; however
no association was observed when genotype frequencies
were compared with matched controls.
Cardinal features of MSA include symptoms of progres-
sive autonomic failure (Gilman et al., 1998). Internal body
functions are maintained and regulated by the autonomic
nervous system (ANS) with norepinephrine (NE) as its
major neurotransmitter. Hence deficiency in NE, caused by
mutations in the dopamine--hydroxylase (DBH) gene, may
e associated with disorders of autonomic function (Cho et
l., 2003). In an association study, patients with orthostatic
ntolerance, pure autonomic failure, MSA, and controls
ere genotyped for 7 mutations in the DBH gene. No
mutations were found, suggesting that the major pathogenic
mechanisms involved in NE deficiency and other autonomic
disorders are fundamentally different (Cho et al., 2003).
Myotonic dystrophy type 2 (DM2), a slowly progressive
multisystem disorder, has been recently associated with
Parkinsonism (Annic et al., 2008). Lim and colleagues re-
ported a case of clinically probable MSA-P, who developed
muscle weakness and genetic testing confirmed 1 abnormal
and 1 normal allele of the ZNF9 gene (Lim et al., 2009).
This is so far the only report on a MSA patient with
abnormalities in the ZNF9 gene.
Likewise, apolipoprotein E (APOE), associated with
Alzheimer’s disease (AD) and DLB, is not considered to be
a player in MSA pathogenesis and does not contribute to an
earlier disease onset (Cairns et al., 1997; Morris et al., 2000,
2001). No disease association has furthermore been de-
tected for genetic variants of the progranulin (PRGN) gene
(Yu et al., 2010).
5. General considerations and limitations of current
studies
Genetic investigation in an apparently sporadic, rare dis-
ease comes with a number of challenges. First, large col-
lections of DNA and tissue samples are required for suffi-
ciently powered studies. This hurdle can be overcome by
depositing samples to brain and DNA banks. Second, the
availability of pathology-proven samples is crucial due to
the high misdiagnosis rate in clinically ascertained cases.
These samples are particularly important to validate poten-
tial risk variants in replication studies. Third, linkage stud-
ies, the standard genetic tool for disease gene identification,
are not feasible in sporadic cases. However, recent advance-
1924.e11S. Stemberger et al. / Neurobiology of Aging 32 (2011) 1924.e5–1924.e14ments in neurogenomics have introduced genome-wide as-
sociation studies and next-generation sequencing techniques
as promising new tools for studying the genetic underpin-
nings of sporadic disease.
6. Conclusions
Within the last 2 decades, extensive studies investigating
the role of genetic players in the pathogenesis of MSA have
established variants in the SNCA locus as the only con-
firmed risk factor in the pathogenesis of MSA. Although
other candidate genes have been implicated, independent
replication studies are still necessary to confirm or refute
these observations. To date, no protein-changing Mendelian
gene mutations have been identified in rare families of
MSA. More advanced genetic tools such as genome-wide
association studies and next-generation sequencing are
likely to unfold the mysterious nature of the beast (Quinn,
1989).
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